Hutchinson-Gilford Progeria Syndrome: Genetic Insights, Clinical Challenges, and Innovative Therapeutic Approaches.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and therapeutic approaches without new primary empirical data
PubMed 42099136 · doi:10.2174/0115665232415170251130041834
What was done
This is a narrative review synthesizing the genetic pathophysiology, diagnostic evaluation, and therapeutic landscape of Hutchinson-Gilford Progeria Syndrome (HGPS), covering current pharmacological management, emerging gene and RNA-based therapies, and interventional cardiovascular approaches.
What was found
The abstract reports no quantitative values or comparative statistics. It notes that lonafarnib (a farnesyltransferase inhibitor) offers modest benefits for survival and reducing progerin accumulation. Additionally, novel experimental strategies—including gene editing, antisense oligonucleotides, isoprenylcysteine carboxyl methyltransferase (ICMT) inhibitors, angiopoietin-2 modulation, and surgical/catheter cardiovascular interventions—are identified as emerging avenues for disease modification.
Why it matters
It outlines the current state and future direction of HGPS treatment, highlighting how therapy is evolving from farnesylation inhibition toward direct genetic and post-translational targeting of progerin.
Limits
The paper is a non-systematic narrative review providing no primary clinical trial or experimental data. The abstract contains no specific sample sizes, effect sizes, survival metrics, or formal assessment of study quality across cited interventions.
Cited by
- supports Children with progeria age prematurely to resemble 80- or 90-year-olds by the age of 7 or 8 due to a single point mutation.